Personal Account
Boundless Bio

Boundless Bio

Biotechnology

Company website
Foundation year

2018

About

A company operating in the field of oncology and currently in the clinical trial phase is seeking to establish a new paradigm in cancer treatment. It focuses on patients with an increased number of oncogenes, targeting extrachromosomal DNA (ecDNA), which is one of the causes of oncogene amplification, found in more than 14% of cancer patients.

The company is registered in Delaware.

Underwriters

Goldman Sachs, Leerink Partners, Piper Sandler, Guggenheim Securities


2022 © All rights reserved

You can always come to our office to discuss any questions with our manager

Dubai

Sharjah Media City, Sharjah, UAE

USA

500 Delaware ave,
STE 1 #1960 Wilmington, DE, USA

Czech Republic

Czech Republic, Prague, Bilkova 855/19

The investment opportunities posted on this website's Pre-IPO section are private placements of securities that are not traded on the open market, subject to the ownership period requirements, and intended for investors who do not require liquid investments. Investments in private companies may be considered speculative, involving high risk, including the significant loss of investment risk. Investors must be able to afford to lose all their investments.